NASDAQ:ACOR - Acorda Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$24.20 +0.65 (+2.76 %)
(As of 05/25/2018 04:00 PM ET)
Previous Close$23.55
Today's Range$23.65 - $25.05
52-Week Range$13.60 - $29.60
Volume795,375 shs
Average Volume572,855 shs
Market Capitalization$1.09 billion
P/E Ratio23.34
Dividend YieldN/A
Beta1.55

About Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics logoAcorda Therapeutics, Inc., a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops Inbrija for the treatment of OFF periods in Parkinson's disease; an inhaled triptan (zolmitriptan) for acute treatment of migraine by using the ARCUS drug delivery technology; SYN120, which is completed Phase II clinical trial to treat Parkinson's disease-related dementia; and BTT1023 (timolumab) that is in Phase II clinical trial for primary sclerosing cholangitis. Further, it develops rHIgM22, which is in Phase I clinical trial for the treatment of MS; and Cimaglermin alfa that is in Phase Ib clinical trial for heart failure patients. The company has collaborations and license agreements with Biogen International GmbH; Alkermes plc; Rush-Presbyterian St. Luke's Medical Center; Alkermes, Inc.; Astellas Pharma Europe Ltd.; Canadian Spinal Research Organization; Mayo Foundation for Education and Research; Paion AG; Medarex, Inc.; and Brigham and Women's Hospital, Inc. Acorda Therapeutics, Inc. was founded in 1995 and is headquartered in Ardsley, New York.

Receive ACOR News and Ratings via Email

Sign-up to receive the latest news and ratings for ACOR and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:ACOR
CUSIP00484M10
Phone914-347-4300

Debt

Debt-to-Equity Ratio0.61
Current Ratio3.65
Quick Ratio3.41

Price-To-Earnings

Trailing P/E Ratio23.34
Forward P/E Ratio-21.80
P/E GrowthN/A

Sales & Book Value

Annual Sales$588.29 million
Price / Sales1.94
Cash Flow$1.8544 per share
Price / Cash13.05
Book Value$11.68 per share
Price / Book2.07

Profitability

EPS (Most Recent Fiscal Year)$1.04
Net Income$-223,350,000.00
Net Margins-36.98%
Return on Equity-3.38%
Return on Assets-1.63%

Miscellaneous

Employees484
Outstanding Shares47,070,000

Acorda Therapeutics (NASDAQ:ACOR) Frequently Asked Questions

What is Acorda Therapeutics' stock symbol?

Acorda Therapeutics trades on the NASDAQ under the ticker symbol "ACOR."

How were Acorda Therapeutics' earnings last quarter?

Acorda Therapeutics (NASDAQ:ACOR) issued its earnings results on Wednesday, May, 2nd. The biopharmaceutical company reported $0.14 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.33 by $0.19. The biopharmaceutical company had revenue of $106.17 million for the quarter, compared to analysts' expectations of $130.94 million. Acorda Therapeutics had a negative return on equity of 3.38% and a negative net margin of 36.98%. The company's revenue for the quarter was down 11.1% on a year-over-year basis. During the same period last year, the business earned ($0.08) EPS. View Acorda Therapeutics' Earnings History.

When is Acorda Therapeutics' next earnings date?

Acorda Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, July, 25th 2018. View Earnings Estimates for Acorda Therapeutics.

What price target have analysts set for ACOR?

13 brokerages have issued 12 month price objectives for Acorda Therapeutics' shares. Their forecasts range from $13.00 to $37.00. On average, they anticipate Acorda Therapeutics' stock price to reach $21.8333 in the next twelve months. View Analyst Ratings for Acorda Therapeutics.

What are Wall Street analysts saying about Acorda Therapeutics stock?

Here are some recent quotes from research analysts about Acorda Therapeutics stock:
  • 1. According to Zacks Investment Research, "Acorda’s earnings missed the Zacks Consesnsus Estimate in the first quarter of 2018. Revenues also fell short of the consensus mark. The company is presently working on strengthening its Parkinson’s pipeline by focusing on the late stage candidate Inbrija in its portfolio. Inbrija’s NDA is under review in the United States and EU. The company’s share price has outperformed the industry so far this year. However, the company’s key multiple sclerosis drug Ampyra is expected to face generic competition from mid-2018 in the United States. Hence, Acorda’s dependence on Ampyra to draw major part of its revenues is concerning. Moreover, Inbrija received a refusal-to-file letter from the FDA for NDA for Inbrija last August. This in turn delayed its expected commercial launch, which was anticipated much earlier." (5/7/2018)
  • 2. HC Wainwright analysts commented, "Ziopharm’s CAR-T Programs Make a Splash at ASH; Reiterate Buy Ziopharm’s 2nd-gen CAR-T shows promise in early study. We attended the 2017 Annual Meeting of the American Society of Hematology (ASH) over the last weekend, where Ziopharm presented interim results from the ongoing Phase 1 clinical study in patients with CD19 + leukemia or lymphoma treated with Ziopharm’s second generation CD19 + CAR-T therapy. Recall, Ziopharm’s second generation CAR-T cells were manufactured using the company’s proprietary Sleeping Beauty (SB) transposon platform which shortens the manufacturing process to two weeks compared to the typical 3-4 weeks for currently approved CAR-T therapies, such as Kymriah from Novartis (NVS; not rated) and Yescarta from Gilead (GILD; not rated). The results from the Phase 1 study show that treatment of patients with relapsed/refractory leukemia or lymphoma (n = 8) resulted in a 50% complete response rate after one month of therapy." (12/14/2017)
  • 3. Cantor Fitzgerald analysts commented, "Not what ACOR stock needed. ACOR announced this morning that an increase in blood monitoring for agranulocytosis is being implemented for subjects in the Phase 3 trial of tozadenant in Parkinson’s disease (PD)." (11/15/2017)

Who are some of Acorda Therapeutics' key competitors?

Who are Acorda Therapeutics' key executives?

Acorda Therapeutics' management team includes the folowing people:
  • Dr. Ron Cohen, Founder, CEO , Pres & Director (Age 62)
  • Mr. David Lawrence, Chief of Bus. Operations & Principal Accounting Officer (Age 60)
  • Ms. Jane Wasman, Pres of International, Gen. Counsel & Corp. Sec. (Age 62)
  • Mr. Andrew Asa Hindman, Chief Bus. Officer (Age 45)
  • Dr. Burkhard Blank M.D., Chief Medical Officer (Age 63)

Has Acorda Therapeutics been receiving favorable news coverage?

Media headlines about ACOR stock have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Acorda Therapeutics earned a media sentiment score of 0.18 on Accern's scale. They also assigned news articles about the biopharmaceutical company an impact score of 44.78 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term.

Who are Acorda Therapeutics' major shareholders?

Acorda Therapeutics' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include SCOPIA CAPITAL MANAGEMENT LP (18.10%), SCOPIA CAPITAL MANAGEMENT LP (18.10%), Dimensional Fund Advisors LP (6.63%), Northern Trust Corp (2.21%), Millennium Management LLC (1.56%) and Spark Investment Management LLC (1.09%). Company insiders that own Acorda Therapeutics stock include Andrew A Hindman, Barry E Greene, Burkhard Blank, David Lawrence, Ian F Smith, Jane Wasman, Lorin Randall, Richard P Batycky, Ron Cohen, Scopia Capital Management Lp and Steven M Rauscher. View Institutional Ownership Trends for Acorda Therapeutics.

Which institutional investors are selling Acorda Therapeutics stock?

ACOR stock was sold by a variety of institutional investors in the last quarter, including Alambic Investment Management L.P., Schwab Charles Investment Management Inc., Guggenheim Capital LLC, American International Group Inc., Teacher Retirement System of Texas, Virginia Retirement Systems ET AL, Diamond Hill Capital Management Inc. and BNP Paribas Arbitrage SA. Company insiders that have sold Acorda Therapeutics company stock in the last year include Barry E Greene, Burkhard Blank, David Lawrence, Ian F Smith, Lorin Randall and Steven M Rauscher. View Insider Buying and Selling for Acorda Therapeutics.

Which institutional investors are buying Acorda Therapeutics stock?

ACOR stock was bought by a variety of institutional investors in the last quarter, including Millennium Management LLC, Dimensional Fund Advisors LP, Water Island Capital LLC, Matarin Capital Management LLC, Spark Investment Management LLC, GSA Capital Partners LLP, Prudential Financial Inc. and Cubist Systematic Strategies LLC. Company insiders that have bought Acorda Therapeutics stock in the last two years include Ron Cohen and Scopia Capital Management Lp. View Insider Buying and Selling for Acorda Therapeutics.

How do I buy shares of Acorda Therapeutics?

Shares of ACOR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acorda Therapeutics' stock price today?

One share of ACOR stock can currently be purchased for approximately $24.20.

How big of a company is Acorda Therapeutics?

Acorda Therapeutics has a market capitalization of $1.09 billion and generates $588.29 million in revenue each year. The biopharmaceutical company earns $-223,350,000.00 in net income (profit) each year or $1.04 on an earnings per share basis. Acorda Therapeutics employs 484 workers across the globe.

How can I contact Acorda Therapeutics?

Acorda Therapeutics' mailing address is 420 SAW MILL RIVER ROAD, ARDSLEY NY, 10502. The biopharmaceutical company can be reached via phone at 914-347-4300.


MarketBeat Community Rating for Acorda Therapeutics (ACOR)

Community Ranking:  2.1 out of 5 (star star)
Outperform Votes:  271 (Vote Outperform)
Underperform Votes:  365 (Vote Underperform)
Total Votes:  636
MarketBeat's community ratings are surveys of what our community members think about Acorda Therapeutics and other stocks. Vote "Outperform" if you believe ACOR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACOR will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Acorda Therapeutics (NASDAQ:ACOR) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
13 Wall Street analysts have issued ratings and price targets for Acorda Therapeutics in the last 12 months. Their average twelve-month price target is $21.8333, suggesting that the stock has a possible downside of 9.78%. The high price target for ACOR is $37.00 and the low price target for ACOR is $13.00. There are currently 1 sell rating, 9 hold ratings and 3 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldHold
Consensus Rating Score: 2.152.152.152.00
Ratings Breakdown: 1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
1 Sell Rating(s)
9 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
2 Sell Rating(s)
9 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $21.8333$21.8333$21.8333$20.6667
Price Target Upside: 9.78% downside7.68% downside13.01% downside16.10% upside

Acorda Therapeutics (NASDAQ:ACOR) Consensus Price Target History

Price Target History for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ:ACOR) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/3/2018HC WainwrightSet Price TargetBuy$31.00LowView Rating Details
5/2/2018OppenheimerSet Price TargetHold$21.00LowView Rating Details
5/2/2018CowenReiterated RatingBuy$30.00HighView Rating Details
2/15/2018Piper Jaffray CompaniesUpgradeNeutral ➝ Overweight$25.10 ➝ $37.00HighView Rating Details
2/7/2018Goldman Sachs GroupUpgradeSell ➝ NeutralLowView Rating Details
1/9/2018JPMorgan Chase & Co.Reiterated RatingHoldLowView Rating Details
11/16/2017Janney Montgomery ScottSet Price TargetHold$26.00 ➝ $17.00N/AView Rating Details
11/16/2017Raymond JamesDowngradeMarket Perform ➝ Underperform$7.00 ➝ $13.00N/AView Rating Details
11/16/2017Stifel NicolausDowngradeBuy ➝ Hold$26.00 ➝ $15.00N/AView Rating Details
11/15/2017Leerink SwannLower Price TargetMarket Perform$18.00N/AView Rating Details
11/15/2017Cantor FitzgeraldLower Price TargetNeutral$18.00 ➝ $16.00N/AView Rating Details
11/9/2017CIBCInitiated CoverageMarket Perform ➝ Market PerformN/AView Rating Details
11/1/2017Jefferies GroupBoost Price TargetHold$22.00 ➝ $25.00N/AView Rating Details
1/8/2017Evercore ISISet Price TargetHold$23.00N/AView Rating Details
6/1/2016AegisBoost Price TargetBuy$40.00 ➝ $52.00N/AView Rating Details
(Data available from 5/25/2016 forward)

Earnings

Acorda Therapeutics (NASDAQ:ACOR) Earnings History and Estimates Chart

Earnings by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ:ACOR) Earnings Estimates

2018 EPS Consensus Estimate: ($0.62)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20183$0.09$0.69$0.36
Q2 20183$0.49$0.84$0.68
Q3 20183($1.28)($0.10)($0.53)
Q4 20183($1.41)($0.65)($1.14)

Acorda Therapeutics (NASDAQ ACOR) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
7/25/2018$0.75N/AView Earnings Details
5/2/2018Q1 2018$0.33$0.14$130.94 million$106.17 millionViewN/AView Earnings Details
2/15/2018Q4 2017$0.88$0.61$171.70 million$188.40 millionViewN/AView Earnings Details
10/31/2017Q3 2017$0.69$0.43$150.64 million$141.07 millionViewN/AView Earnings Details
7/27/2017Q2 2017$0.13$0.29$139.81 million$139.40 millionViewN/AView Earnings Details
4/27/2017Q1 2017($0.16)($0.08)$127.34 million$119.39 millionViewN/AView Earnings Details
2/14/2017Q416($0.18)$0.05$137.90 million$140.63 millionViewListenView Earnings Details
10/27/2016Q316($0.26)($0.04)$134.01 million$135.61 millionViewListenView Earnings Details
7/28/2016Q216$0.18$0.07$128.33 million$127.45 millionViewListenView Earnings Details
4/28/2016Q116$0.08$0.07$115.36 million$115.90 millionViewListenView Earnings Details
2/11/2016Q415$0.22$0.28$128.24 million$130.90 millionViewListenView Earnings Details
10/22/2015Q315$0.15$0.31$115.52 million$148.20 millionViewListenView Earnings Details
7/30/2015Q215($0.01)$0.31$110.84 million$113.70 millionViewListenView Earnings Details
4/30/2015Q115$0.03($0.02)$100.20 million$99.85 millionViewN/AView Earnings Details
2/12/2015Q414$0.15$0.33$110.80 million$117.90 millionViewN/AView Earnings Details
10/30/2014Q314$0.04$0.34$94.70 million$106.00 millionViewN/AView Earnings Details
7/31/2014Q214$0.14$0.24$91.40 million$97.13 millionViewN/AView Earnings Details
5/6/2014Q114$0.04$0.08$81.30 million$80.52 millionViewN/AView Earnings Details
2/19/2014Q413$0.18$0.32$89.96 million$92.59 millionViewN/AView Earnings Details
10/31/2013Q313$0.13$0.36$90.01 million$84.92 millionViewListenView Earnings Details
8/1/2013Q2 2013$0.09$0.25$82.57 million$87.05 millionViewListenView Earnings Details
5/2/2013Q1 2013$0.20$0.09$80.77 million$71.90 millionViewListenView Earnings Details
2/13/2013Q4 2012$0.15$0.24$78.90 million$81.47 millionViewListenView Earnings Details
10/31/2012Q312$0.10$0.38$75.20 million$77.44 millionViewN/AView Earnings Details
7/31/2012$0.27$0.27ViewN/AView Earnings Details
5/3/2012$0.27$0.36ViewN/AView Earnings Details
2/16/2012$0.24$0.40ViewN/AView Earnings Details
11/4/2011$0.82$0.47ViewN/AView Earnings Details
8/1/2011$0.10$0.01ViewN/AView Earnings Details
5/5/2011$0.17($0.02)ViewN/AView Earnings Details
2/17/2011$0.17$0.09ViewN/AView Earnings Details
11/1/2010Q3 2010($0.12)$0.31ViewN/AView Earnings Details
8/3/2010Q2 2010($0.46)($0.18)ViewN/AView Earnings Details
4/30/2010Q1 2010($0.54)($0.56)ViewN/AView Earnings Details
2/23/2010Q4 2009($0.60)($0.59)ViewN/AView Earnings Details
11/3/2009Q3 2009($0.59)($0.52)ViewN/AView Earnings Details
8/4/2009Q2 2009($0.54)($0.62)ViewN/AView Earnings Details
5/6/2009Q1 2009($0.55)($0.50)ViewN/AView Earnings Details
2/24/2009Q4 2008($0.52)($0.54)ViewN/AView Earnings Details
11/4/2008Q3 2008($0.47)($0.53)ViewN/AView Earnings Details
8/5/2008Q2 2008($0.47)($0.58)ViewN/AView Earnings Details
5/5/2008Q1 2008($0.41)($0.45)ViewN/AView Earnings Details
2/11/2008Q4 2007($0.31)($0.48)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Acorda Therapeutics (NASDAQ:ACOR) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Acorda Therapeutics (NASDAQ ACOR) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.80%
Insider Trading History for Acorda Therapeutics (NASDAQ:ACOR)
Institutional Ownership by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Acorda Therapeutics (NASDAQ ACOR) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/18/2018Burkhard BlankInsiderSell25,000$23.66$591,500.0058,150View SEC Filing  
5/15/2018Steven M RauscherDirectorSell10,000$24.59$245,900.0010,000View SEC Filing  
5/2/2018Ian F SmithDirectorSell10,000$23.72$237,200.0010,000View SEC Filing  
1/19/2018David LawrenceInsiderSell31,000$27.58$854,980.005,275View SEC Filing  
12/1/2017Burkhard BlankInsiderSell11,050$20.53$226,856.5033,150View SEC Filing  
10/9/2017David LawrenceInsiderSell250$25.40$6,350.00View SEC Filing  
8/29/2017Scopia Capital Management LpMajor ShareholderBuy766,201$19.23$14,734,045.23View SEC Filing  
8/1/2017Barry E GreeneDirectorSell10,000$21.57$215,700.0010,000View SEC Filing  
7/31/2017Lorin RandallDirectorSell10,000$21.66$216,600.0010,000View SEC Filing  
6/16/2017Ron CohenInsiderBuy20,000$16.95$339,000.00511,648View SEC Filing  
5/15/2017Andrew A HindmanInsiderSell7,704$15.75$121,338.0046,123View SEC Filing  
12/14/2016Ron CohenInsiderSell40,172$20.75$833,569.00519,860View SEC Filing  
10/21/2016Richard P BatyckyInsiderSell2,063$20.30$41,878.9045,916View SEC Filing  
10/7/2016David LawrenceInsiderSell250$20.82$5,205.008,952View SEC Filing  
10/3/2016Jane WasmanInsiderSell3,750$20.78$77,925.00105,021View SEC Filing  
9/23/2016Jane WasmanInsiderSell500$27.32$13,660.00109,271View SEC Filing  
6/22/2016David LawrenceInsiderSell500$25.09$12,545.009,702View SEC Filing  
6/8/2016Steven M RauscherDirectorSell1,086$27.83$30,223.381,086View SEC Filing  
5/13/2016Andrew A HindmanInsiderSell4,860$26.11$126,894.6049,670View SEC Filing  
4/19/2016Lorin RandallDirectorSell1,488$28.68$42,675.841,488View SEC Filing  
1/4/2016Ian F. SmithDirectorSell13,231$41.85$553,717.35View SEC Filing  
12/23/2015Jane WasmaninsiderSell10,751$43.10$463,368.10100,124View SEC Filing  
12/22/2015Lauren M. SabellainsiderSell7,113$42.04$299,030.5214,378View SEC Filing  
12/21/2015Jane WasmanInsiderSell817$42.00$34,314.00108,579View SEC Filing  
12/18/2015David LawrenceinsiderSell39,026$40.63$1,585,626.389,202View SEC Filing  
12/17/2015Lauren M. SabellainsiderSell14,229$40.00$569,160.0014,378View SEC Filing  
12/1/2015Enrique J CarrazanaInsiderSell7,218$38.08$274,861.4432,148View SEC Filing  
12/1/2015Ron CohenCEOSell11,850$38.08$451,248.00400,550View SEC Filing  
10/19/2015Andrew BlightinsiderSell32,500$30.87$1,003,275.0071,659View SEC Filing  
10/7/2015Michael W. RogersCFOSell5,700$30.24$172,368.0041,677View SEC Filing  
10/5/2015Jane WasmaninsiderSell3,750$31.75$119,062.5098,097View SEC Filing  
10/5/2015Ron CohenCEOSell135,000$28.03$3,784,050.00412,400View SEC Filing  
9/21/2015Andrew BlightinsiderSell13,085$31.30$409,560.5071,659View SEC Filing  
5/15/2015Andrew A HindmanInsiderSell4,779$29.82$142,509.78View SEC Filing  
1/12/2015Enrique J CarrazanaInsiderSell97,993$42.21$4,136,284.53View SEC Filing  
12/18/2014David LawrenceInsiderSell27,109$40.11$1,087,341.99View SEC Filing  
12/18/2014John P KelleyDirectorSell10,000$40.00$400,000.00View SEC Filing  
12/1/2014David LawrenceInsiderSell8,898$35.60$316,768.80View SEC Filing  
12/1/2014Lauren M SabellaVPSell3,242$35.58$115,350.36View SEC Filing  
12/1/2014Michael W RogersCFOSell230$35.58$8,183.40View SEC Filing  
12/1/2014Ron CohenCEOSell34,394$35.59$1,224,082.46View SEC Filing  
10/7/2014Michael W RogersCFOSell5,700$33.10$188,670.00View SEC Filing  
10/3/2014Jane WasmanInsiderSell3,750$34.13$127,987.50View SEC Filing  
9/24/2014Jane WasmanInsiderSell14,923$36.00$537,228.00View SEC Filing  
8/27/2014Jane WasmanInsiderSell14,923$33.00$492,459.00View SEC Filing  
12/5/2013Lauren SabellaVPSell8,797$31.81$279,832.5712,403View SEC Filing  
12/2/2013Enrique CarrazanaInsiderSell1,640$33.56$55,038.4032,527View SEC Filing  
10/15/2013Enrique J CarrazanaInsiderSell3,333$32.38$107,922.54View SEC Filing  
10/3/2013Jane WasmanInsiderSell3,750$35.74$134,025.00105,459View SEC Filing  
8/20/2013Ron CohenCEOSell149,000$34.10$5,080,900.00478,868View SEC Filing  
8/2/2013John KelleyDirectorSell15,000$38.00$570,000.00View SEC Filing  
7/19/2013Andrew BlightInsiderSell19,296$37.82$729,774.72View SEC Filing  
6/10/2013Ron CohenCEOSell11,000$34.15$375,650.00View SEC Filing  
5/8/2013Sandra Phd PanemDirectorSell10,000$33.80$338,000.00View SEC Filing  
12/4/2012Lauren M SabellaVPSell4,364$24.58$107,267.12View SEC Filing  
12/3/2012Andrew BlightInsiderSell7,200$24.20$174,240.00View SEC Filing  
12/3/2012David LawrenceCFOSell9,313$24.21$225,467.73View SEC Filing  
12/3/2012Ron CohenCEOSell16,407$24.22$397,377.54View SEC Filing  
11/13/2012Sandra Phd PanemDirectorSell22,569$24.12$544,364.28View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Acorda Therapeutics (NASDAQ ACOR) News Headlines

Source:
DateHeadline
Acorda Therapeutics (ACOR) Receives Consensus Recommendation of "Hold" from AnalystsAcorda Therapeutics (ACOR) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 25 at 3:41 PM
Bullish Two Hundred Day Moving Average Cross - ACORBullish Two Hundred Day Moving Average Cross - ACOR
www.nasdaq.com - May 24 at 4:57 PM
Zacks: Brokerages Anticipate Acorda Therapeutics (ACOR) Will Announce Quarterly Sales of $124.79 MillionZacks: Brokerages Anticipate Acorda Therapeutics (ACOR) Will Announce Quarterly Sales of $124.79 Million
www.americanbankingnews.com - May 24 at 1:55 AM
Form 4 ACORDA THERAPEUTICS INC For: May 18 Filed by: BLANK BURKHARDForm 4 ACORDA THERAPEUTICS INC For: May 18 Filed by: BLANK BURKHARD
www.streetinsider.com - May 23 at 4:59 PM
 Brokerages Expect Acorda Therapeutics (ACOR) to Announce $0.68 EPS Brokerages Expect Acorda Therapeutics (ACOR) to Announce $0.68 EPS
www.americanbankingnews.com - May 22 at 11:10 PM
Acorda Therapeutics (ACOR) Insider Sells $591,500.00 in StockAcorda Therapeutics (ACOR) Insider Sells $591,500.00 in Stock
www.americanbankingnews.com - May 22 at 7:28 PM
BRIEF-FDA Says Making List Of Cos Blocking Access To Samples Of Branded ProductsBRIEF-FDA Says Making List Of Cos Blocking Access To Samples Of Branded Products
www.reuters.com - May 18 at 5:05 PM
Acorda Therapeutics (ACOR) Director Sells $245,900.00 in StockAcorda Therapeutics (ACOR) Director Sells $245,900.00 in Stock
www.americanbankingnews.com - May 17 at 10:15 AM
Global Parkinsons Disease Drugs and Therapeutics Market Growth Opportunities: Novartis AG, Pfizer Inc.Global Parkinsons Disease Drugs and Therapeutics Market Growth Opportunities: Novartis AG, Pfizer Inc.
www.marketwatch.com - May 16 at 9:12 AM
Stock Traders Buy High Volume of Put Options on Acorda Therapeutics (ACOR)Stock Traders Buy High Volume of Put Options on Acorda Therapeutics (ACOR)
www.americanbankingnews.com - May 16 at 6:37 AM
BidaskClub Downgrades Acorda Therapeutics (ACOR) to HoldBidaskClub Downgrades Acorda Therapeutics (ACOR) to Hold
www.americanbankingnews.com - May 10 at 11:58 AM
Acorda Therapeutics (ACOR) Downgraded to "Sell" at Zacks Investment ResearchAcorda Therapeutics (ACOR) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - May 7 at 11:31 AM
Zacks: Brokerages Anticipate Acorda Therapeutics (ACOR) Will Post Quarterly Sales of $144.17 MillionZacks: Brokerages Anticipate Acorda Therapeutics (ACOR) Will Post Quarterly Sales of $144.17 Million
www.americanbankingnews.com - May 7 at 4:04 AM
 Brokerages Expect Acorda Therapeutics (ACOR) to Announce $0.91 Earnings Per Share Brokerages Expect Acorda Therapeutics (ACOR) to Announce $0.91 Earnings Per Share
www.americanbankingnews.com - May 5 at 1:41 PM
Acorda Therapeutics (ACOR) Upgraded by BidaskClub to "Buy"Acorda Therapeutics (ACOR) Upgraded by BidaskClub to "Buy"
www.americanbankingnews.com - May 5 at 1:07 AM
Insider Selling: Acorda Therapeutics (ACOR) Director Sells 10,000 Shares of StockInsider Selling: Acorda Therapeutics (ACOR) Director Sells 10,000 Shares of Stock
www.americanbankingnews.com - May 4 at 7:52 PM
Acorda Therapeutics (ACOR) Upgraded by ValuEngine to BuyAcorda Therapeutics (ACOR) Upgraded by ValuEngine to Buy
www.americanbankingnews.com - May 3 at 11:47 PM
Acorda Therapeutics (ACOR) Given a $21.00 Price Target by Oppenheimer AnalystsAcorda Therapeutics (ACOR) Given a $21.00 Price Target by Oppenheimer Analysts
www.americanbankingnews.com - May 3 at 9:58 PM
Acorda Therapeutics, Inc. 2018 Q1 - Results - Earnings Call SlidesAcorda Therapeutics, Inc. 2018 Q1 - Results - Earnings Call Slides
seekingalpha.com - May 3 at 4:47 PM
HC Wainwright Analysts Give Acorda Therapeutics (ACOR) a $31.00 Price TargetHC Wainwright Analysts Give Acorda Therapeutics (ACOR) a $31.00 Price Target
www.americanbankingnews.com - May 3 at 12:52 PM
Edited Transcript of ACOR earnings conference call or presentation 2-May-18 12:30pm GMTEdited Transcript of ACOR earnings conference call or presentation 2-May-18 12:30pm GMT
finance.yahoo.com - May 3 at 8:57 AM
Form 8-K ACORDA THERAPEUTICS INC For: May 02Form 8-K ACORDA THERAPEUTICS INC For: May 02
www.streetinsider.com - May 2 at 4:55 PM
Acorda Therapeutics (ACOR) CEO Ron Cohen on Q1 2018 Results - Earnings Call TranscriptAcorda Therapeutics' (ACOR) CEO Ron Cohen on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 2 at 4:55 PM
Acorda Therapeutics (ACOR) Given Buy Rating at CowenAcorda Therapeutics (ACOR) Given Buy Rating at Cowen
www.americanbankingnews.com - May 2 at 1:09 PM
Acorda Therapeutics (ACOR) Issues  Earnings ResultsAcorda Therapeutics (ACOR) Issues Earnings Results
www.americanbankingnews.com - May 2 at 12:56 PM
Acorda Therapeutics misses by $0.33, misses on revenueAcorda Therapeutics misses by $0.33, misses on revenue
seekingalpha.com - May 2 at 8:59 AM
BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14BRIEF-Acorda Therapeutics Reports Q1 Non-GAAP Earnings Per Share Of $0.14
www.reuters.com - May 2 at 8:59 AM
Acorda: 1Q Earnings SnapshotAcorda: 1Q Earnings Snapshot
finance.yahoo.com - May 2 at 8:59 AM
Acorda Therapeutics (ACOR) Given Average Rating of "Hold" by BrokeragesAcorda Therapeutics (ACOR) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - April 30 at 5:34 PM
Acorda Therapeutics (ACOR) Upgraded by Zacks Investment Research to HoldAcorda Therapeutics (ACOR) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 24 at 12:47 PM
Parkinsons Disease Therapeutics Market to Exceed the US$ 5.24 Bn by 2025, Says TMRParkinson's Disease Therapeutics Market to Exceed the US$ 5.24 Bn by 2025, Says TMR
www.prnewswire.com - April 23 at 8:48 AM
Epilepsy: Competitive Landscape, Market and Pipeline Analysis 2018 - Analysis of 115+ Therapeutic Drugs ...Epilepsy: Competitive Landscape, Market and Pipeline Analysis 2018 - Analysis of 115+ Therapeutic Drugs ...
www.businesswire.com - April 21 at 8:54 AM
An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR…)An Ear To The Pharma: 10 Stocks To Watch (BHVN, LLY, TOCA, ALDR…)
www.nasdaq.com - April 21 at 8:54 AM
Acorda Therapeutics (ACOR) Downgraded to Hold at BidaskClubAcorda Therapeutics (ACOR) Downgraded to Hold at BidaskClub
www.americanbankingnews.com - April 21 at 7:06 AM
Acorda Therapeutics (ACOR) Expected to Post Quarterly Sales of $125.73 MillionAcorda Therapeutics (ACOR) Expected to Post Quarterly Sales of $125.73 Million
www.americanbankingnews.com - April 20 at 2:52 AM
BidaskClub Downgrades Acorda Therapeutics (ACOR) to BuyBidaskClub Downgrades Acorda Therapeutics (ACOR) to Buy
www.americanbankingnews.com - April 18 at 4:44 PM
Acorda Therapeutics (ACOR) Expected to Announce Earnings of $0.73 Per ShareAcorda Therapeutics (ACOR) Expected to Announce Earnings of $0.73 Per Share
www.americanbankingnews.com - April 18 at 11:14 AM
Acorda Therapeutics (ACOR) Rating Lowered to Strong Sell at Zacks Investment ResearchAcorda Therapeutics (ACOR) Rating Lowered to Strong Sell at Zacks Investment Research
www.americanbankingnews.com - April 18 at 10:12 AM
Acorda Therapeutics (ACOR) Set to Announce Earnings on WednesdayAcorda Therapeutics (ACOR) Set to Announce Earnings on Wednesday
www.americanbankingnews.com - April 18 at 3:44 AM
Global Parkinsons Disease Drugs and Therapeutics Market Overview 2017-2026: Merck & Co.Global Parkinsons Disease Drugs and Therapeutics Market Overview 2017-2026: Merck & Co.
www.marketwatch.com - April 16 at 8:55 AM
Acorda to Present New Data For INBRIJA™ (levodopa inhalation powder) at 70th American Academy of Neurology Annual MeetingAcorda to Present New Data For INBRIJA™ (levodopa inhalation powder) at 70th American Academy of Neurology Annual Meeting
finance.yahoo.com - April 16 at 8:55 AM
Acorda Therapeutics (ACOR) Receives "Buy" Rating from Stifel NicolausAcorda Therapeutics (ACOR) Receives "Buy" Rating from Stifel Nicolaus
www.americanbankingnews.com - April 15 at 11:33 AM
BidaskClub Downgrades Acorda Therapeutics (ACOR) to SellBidaskClub Downgrades Acorda Therapeutics (ACOR) to Sell
www.americanbankingnews.com - April 14 at 8:31 AM
Assessing Acorda Therapeutics’ Cash FlowAssessing Acorda Therapeutics’ Cash Flow
finance.yahoo.com - April 9 at 9:12 AM
Acorda Therapeutics (ACOR) Rating Increased to Hold at ValuEngineAcorda Therapeutics (ACOR) Rating Increased to Hold at ValuEngine
www.americanbankingnews.com - April 8 at 2:04 PM
Analysts’ Ratings for FibroGen and Its Peers in April 2018Analysts’ Ratings for FibroGen and Its Peers in April 2018
finance.yahoo.com - April 6 at 9:18 AM
Acorda Therapeutics Inc (ACOR) Given Consensus Recommendation of "Hold" by BrokeragesAcorda Therapeutics Inc (ACOR) Given Consensus Recommendation of "Hold" by Brokerages
www.americanbankingnews.com - April 5 at 3:34 PM
Acorda Therapeutics (ACOR) Lowered to "Strong Sell" at Zacks Investment ResearchAcorda Therapeutics (ACOR) Lowered to "Strong Sell" at Zacks Investment Research
www.americanbankingnews.com - April 4 at 12:25 PM
Acorda Therapeutics Inc (ACOR) Expected to Post Quarterly Sales of $125.73 MillionAcorda Therapeutics Inc (ACOR) Expected to Post Quarterly Sales of $125.73 Million
www.americanbankingnews.com - April 3 at 3:39 AM
Jefferies Group Raises Acorda Therapeutics (ACOR) Price Target to $25.00Jefferies Group Raises Acorda Therapeutics (ACOR) Price Target to $25.00
www.americanbankingnews.com - April 2 at 11:56 AM

SEC Filings

Acorda Therapeutics (NASDAQ:ACOR) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Acorda Therapeutics (NASDAQ:ACOR) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Acorda Therapeutics (NASDAQ ACOR) Stock Chart for Friday, May, 25, 2018

Loading chart…

This page was last updated on 5/25/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.